Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 50, Issue 4, 2017, Pages

  van Manen, Mirjam J G ^a   Birring, Surinder S ^b   Vancheri, Carlo ^c   Vindigni, Virginia ^c   Renzoni, Elisabetta ^d   Russell, Anne Marie ^d,e   Wapenaar, Monique ^a   Cottin, Vincent ^f   Wijsenbeek, Marlies S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CATANIA   (Italy)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; PIRFENIDONE; ANTITUSSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL PRACTICE; COUGHING; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FRANCE; GENERALIZED ANXIETY DISORDER-7; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; ITALY; KINGS BRIEF INTERSTITIAL LUNG DISEASE HEALTH STATUS QUESTIONNAIRE; LETTER; LUNG TRANSFER FACTOR; NETHERLANDS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SENSITIVITY ANALYSIS; STUDENT T TEST; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; CLINICAL TRIAL; FEMALE; LUNG FUNCTION TEST; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROCEDURES; SELF EVALUATION; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITUSSIVE AGENTS; COUGH; DIAGNOSTIC SELF EVALUATION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDONES; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 85054775076     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01157-2017     Document Type: Letter

References (16)

1. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). The voice of the patient; a series of reports from the U.S. Food and Drug Administration's (FDA's) Patient-Focused Drug Development Initiative. Idiopathic Pulmonary Fibrosis. March 2015. www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM440829.pdf Date last updated: March 2015. Date last accessed: January 2017.
2. Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010; 6: 4.
3. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969-975.
4. Hope-Gill BDM, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 995-1002.
5. Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12: 143.
6. Okazaki A, Ohkura N, Fujimura M, et al. Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs. Pulm Pharmacol Ther 2013; 26: 603-608.
7. Birring SS, Fleming T, Matos S, et al. The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 2008; 31: 1013-1018.
8. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67: 804-810.
9. Raj AA, Pavord DI, Birring SS. Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire? Handb Exp Pharmacol 2009; 187: 311-320.
10. Chakraborty H, Gu H. A mixed model approach for intent-to-treat analysis in longitudinal clinical trials with missing values. RTI Press 2009; MR-0009-0903: 1-10.
11. Didiasova M, Singh R, Wilhelm J, et al. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB J 2017; 31: 1916-1928.
12. Froese AR, Shimbori C, Bellaye PS, et al. Stretch-induced activation of transforming growth factor-beta1 in pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 84-96.
13. Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med 2012; 136: 591-600.
14. Kilduff CE, Counter MJ, Thomas GA, et al. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough 2014; 10: 4.
15. Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157: 398-406.
16. Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med 2017; 5: 806-815.